Search Result

Results for "

3CL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Amino Acid Derivatives (1) Antibiotic (1) Apoptosis (5) Bacterial (1) Cathepsin (2) CXCR (1) Cytochrome P450 (2) Endogenous Metabolite (2) G protein-coupled Bile Acid Receptor 1 (1) HBV (1) HCV (15) HCV Protease (12) HIV (12) HIV Protease (12) HSV (2) Influenza Virus (1) Isotope-Labeled Compounds (1) MMP (3) Opioid Receptor (2) P-glycoprotein (2) Parasite (1) PROTAC Linkers (1) SARS-CoV (65) Small Interfering RNA (siRNA) (1) Virus Protease (7)
By Research Areas:	Cancer (16) Infection (65) Inflammation/Immunology (8) Metabolic Disease (3) Neurological Disease (2)

By Targets:

Adenosine Receptor (2)

Amino Acid Derivatives (1)

Antibiotic (1)

Apoptosis (5)

Bacterial (1)

Cathepsin (2)

CXCR (1)

Cytochrome P450 (2)

Endogenous Metabolite (2)

G protein-coupled Bile Acid Receptor 1 (1)

HBV (1)

HCV (15)

HCV Protease (12)

HIV (12)

HIV Protease (12)

HSV (2)

Influenza Virus (1)

Isotope-Labeled Compounds (1)

MMP (3)

Opioid Receptor (2)

P-glycoprotein (2)

Parasite (1)

PROTAC Linkers (1)

SARS-CoV (65)

Small Interfering RNA (siRNA) (1)

Virus Protease (7)

By Research Areas:

Cancer (16)

Infection (65)

Inflammation/Immunology (8)

Metabolic Disease (3)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146998

SARS-CoV-2 3CLpro-IN-2	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .

HY-147020

Coronastat NK01-63	SARS-CoV	Infection
Coronastat is a potent inhibitor of the *SARS-CoV-2 3CL* protease*. The SARS-CoV-2 3CL* protease is a critical agent target for small molecule COVID-19, given its likely agentgability and essentiality in the viral maturation and replication cycle .

HY-157778

MK-7845

SARS-CoV Infection

MK-7845 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ of 8.7 nM .

MK-7845	SARS-CoV	Infection
MK-7845 is a reversible covalent *SARS-CoV-2 3CL* protease inhibitor with an IC₅₀** of 8.7 nM .

HY-150691

SARS 3CLpro-IN-1	SARS-CoV	Cancer
SARS 3CLpro-IN-1 (Compound 3b) is a *SARS 3CL* protease inhibitor with an IC₅₀** value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .

HY-152005

SARS-CoV-2 3CLpro-IN-6	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL ^pro with an IC₅₀ value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-N8471

Niazinin	Parasite SARS-CoV	Infection Inflammation/Immunology
Niazinin is a thiocarbamate glycoside with antileishmanial activities, with an IC₅₀ value of 5.25 μM. Niazinin also shows a binding affinity with the target protein 3CL protease. Niazinin has promising leishmanicidal, anti-inflammatory and anti-pyretic activity .

HY-139311

YH-53	SARS-CoV	Infection
YH-53 is a potent 3CL ^pro inhibitor with K_i values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CL ^pro and SARS-CoV-2 3CL ^pro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research .

HY-163067

SARS-CoV-2-IN-71	SARS-CoV	Infection
SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL ^pro and TMPRSS2 .

HY-149655

D1N8	SARS-CoV	Infection
D1N8 is a potent *SARS-CoV-2 3CL* ^pro** inhibitor with an IC₅₀ and CC₅₀ values of 0.44 μM and >20 μM, respectively. D1N8 has the potential for the research of anti-SARS-CoV-2 agents targeting 3CL ^pro .

HY-144062

INSCoV-614(1B)	SARS-CoV	Infection
INSCoV-614(1B) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-132306

CCF0058981 CCF981	SARS-CoV Virus Protease	Infection
CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent *SARS-CoV-2 3CL* ^pro (SC2) inhibitor with an IC₅₀ of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL ^pro) with an IC₅₀ of 19 nM. CCF0058981 has antiviral** efficacy and has the potential for COVID-19 research .

HY-144061

INSCoV-601I(1)	SARS-CoV	Infection
INSCoV-601I(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144063

INSCoV-600K(1)	SARS-CoV	Infection
INSCoV-600K(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-149656

D1N52

SARS-CoV Infection

D1N52 is a potent SARS-CoV-2 3CL ^pro inhibitor with an IC₅₀ of 0.53 μM .

D1N52	SARS-CoV	Infection
D1N52 is a potent *SARS-CoV-2 3CL* ^pro inhibitor with an IC₅₀** of 0.53 μM .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of *SARS-CoV-2 3CL* ^pro*. 3CL* ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-137048

PF-00835231 1 Publications Verification	SARS-CoV	Infection
PF-00835231 is a CoV-2 *cysteine 3C-like protease (3CL* ^pro) inhibitor, with IC₅₀*s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL* ^pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19 sup>[2].

HY-139683

Antiviral agent 5

SARS-CoV Infection

Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 M ^pro.

Antiviral agent 5	SARS-CoV	Infection
Antiviral agent 5 is an intermediate used in antiviral agents targeting 3C and 3CL proteases including SARS-CoV-2 M ^pro.

HY-17007

Saquinavir 5+ Cited Publications Ro 31-8959	HIV HIV Protease SARS-CoV	Infection Cancer
Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.36 μM.

HY-156654

Ibuzatrelvir PF-07817883	SARS-CoV Virus Protease	Infection
Ibuzatrelvir (PF-07817883) is an antiviral agent, targeting to SARS-CoV-2 3CL protease. Ibuzatrelvir can be used to inhibit COVID-19 .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of *SARS-CoV-2 3CL* protease** (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of *SARS-CoV-2 3CL* protease** (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-90001

Ritonavir 20+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.61 μM.

HY-143216

Ensitrelvir 5+ Cited Publications S-217622	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, *SARS-CoV-2 3CL* protease inhibitor (IC₅₀**=13 nM) .

HY-143216A

Ensitrelvir fumarate 5+ Cited Publications S-217622 fumarate	SARS-CoV Virus Protease	Infection
Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, *SARS-CoV-2 3CL* protease inhibitor (IC₅₀**=13 nM) .

HY-152009

SARS-CoV-2 3CLpro-IN-7

SARS-CoV Infection

SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 1.4 µM .

SARS-CoV-2 3CLpro-IN-7	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent *SARS-CoV-2 3CL* protease inhibitor with an IC₅₀** value of 1.4 µM .

HY-152589

Antiviral agent 25	SARS-CoV	Infection
Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of *SARS-CoV-2 3CL* ^pro*. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CL* ^pro and SARS-CoV-2 PL ^pro with IC₅₀ values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC₅₀ value of 7.249 µM .

HY-17430

Amprenavir 5+ Cited Publications VX-478	HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.09 μM.

HY-153228

Pomotrelvir PBI-0451	SARS-CoV	Infection
Pomotrelvir (PBI-0451) is a selective, orally active SARS-CoV-2 3CL protease inhibitor. Pomotrelvir has antiviral activity and can be used in the research of novel coronavirus (COVID-19) .

HY-108137

Z-LVG-CHN2 2 Publications Verification	Cathepsin HSV SARS-CoV	Infection Inflammation/Immunology
Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease ^[3].

HY-151535

SARS-CoV-2 3CLpro-IN-5	SARS-CoV	Infection Inflammation/Immunology
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of *3C-like protease (3CL* ^pro)*. SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL* ^pro with an IC₅₀ value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-17634

Glecaprevir 5 Publications Verification ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 4.09 μM .

HY-154965

Simnotrelvir SIM0417; SARS-CoV-2-IN-41	SARS-CoV	Infection
SARS-CoV-2-IN-41 (compound 2) is a potent *SARS-CoV-2 3CL* ^pro inhibitor with an IC₅₀** value of 0.022 µM. SARS-CoV-2-IN-41 shows antiviral effect .

HY-18219

Walrycin B 1 Publications Verification	SARS-CoV Bacterial Antibiotic	Infection Inflammation/Immunology
Walrycin B, an analogue of toxoflavin, is a potent *SARS-CoV-2 3CL* ^pro inhibitor with an IC₅₀ of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria** growth .

HY-90001R

Ritonavir (Standard) ABT 538 (Standard); RTV (Standard)	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (Standard) is the analytical standard of Ritonavir. This product is intended for research and analytical applications. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.61 μM.

HY-14434

Asunaprevir 30+ Cited Publications BMS-650032	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC₅₀ of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-156651

Zevotrelvir	SARS-CoV	Infection
Zevotrelvir (Compound 52) is a coronavirus inhibitor with IC₅₀ ranges of <0.1 μM and <0.1mM for 229E hCoV and *SARS-CoV-23C-like (3CL) proteases*, respectively. Zevotrelvir has the potential to study viral infections .

HY-133862

SCH-202676	Influenza Virus G protein-coupled Bile Acid Receptor 1 Adenosine Receptor	Infection
SCH-202676 is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 has antiviral activity and inhibits 3CL ^pro in a time-dependent manner with an IC₅₀ value of 0.655 µM ^[3] .

HY-149264

SARS-CoV-2 3CLpro-IN-13	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-13 is a potent *SARS-CoV-2 3CL* protease inhibitor with an IC₅₀** value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .

HY-138687

Nirmatrelvir Maximum Cited Publications 44 Publications Verification PF-07321332	SARS-CoV	Infection Inflammation/Immunology
Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL ^PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .

HY-108137A

Z-L(D-Val)G-CHN2	Cathepsin HSV SARS-CoV	Infection
Z-L(D-Val)G-CHN2 is the isoform of Z-LVG-CHN2 (HY-108137). Z-LVG-CHN2 is a cell-permeable and irreversible inhibitor of cysteine proteinase. Z-LVG-CHN2 is a tripeptide derivative and mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 displays an inhibition on HSV whereas no significant effect on poliovirus replication. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC₅₀=190 nM) via inhibition of SARS-COV-2 3CL pro protease ^[3].

HY-15602

Ledipasvir 25+ Cited Publications GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.62 μM ^[3].

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 1.62 μM ^[3].

HY-110012

SCH-202676 hydrobromide	Adenosine Receptor	Infection
SCH-202676 hydrobromide is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 hydrobromide has antiviral activity and inhibits 3CL ^pro in a time-dependent manner with an IC₅₀ value of 0.655 μM ^[3] .

HY-10300

Narlaprevir 4 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 2.3 μM ^[3].

HY-10237

Boceprevir 25+ Cited Publications EBP 520; SCH 503034	HCV Protease HCV SARS-CoV	Infection
Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay ^[3] . Boceprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-12530

Velpatasvir 5+ Cited Publications GS-5816	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 2.16 μM .

HY-149767

CMX990	SARS-CoV	Infection
CMX990 is a SARS-CoV-2 3CL protease inhibitor. The EC90s for inhibiting SARS-CoV-2 were 9.6 nM and 101 nM in human bronchial epithelial cells (HBECs) and HeLa-ACE2 cells, respectively. CMX990 has good ADME and pharmacokinetic properties .

HY-B0689

Indinavir MK-639 free base; L-735524 free base	HIV HIV Protease Apoptosis MMP SARS-CoV	Inflammation/Immunology Cancer
Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a *SARS-CoV 3CL* ^pro** inhibitor ^[3] .

HY-15148

Tipranavir 5+ Cited Publications PNU-140690	HIV Protease HIV SARS-CoV	Infection
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC₅₀s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL ^pro activity ^[3].

HY-B0689A

Indinavir sulfate 5+ Cited Publications MK-639; L735524	HIV HIV Protease SARS-CoV Apoptosis MMP	Infection Cancer
Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a K_i of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a *SARS-CoV 3CL* ^pro** inhibitor ^[3] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8471

Niazinin	Natural Products Classification of Application Fields Moringa oleifera Lam. Source classification Moringaceae Plants Disease Research Fields Inflammation/Immunology	Parasite SARS-CoV
Niazinin is a thiocarbamate glycoside with antileishmanial activities, with an IC₅₀ value of 5.25 μM. Niazinin also shows a binding affinity with the target protein 3CL protease. Niazinin has promising leishmanicidal, anti-inflammatory and anti-pyretic activity .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of *CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)* . Atazanavir is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 3.49 μM ^[3].

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of *CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)* . Atazanavir sulfate is also a *SARS-CoV 3CL* ^pro inhibitor with an IC₅₀** of 3.49 μM ^[3].

HY-N0063

Punicalagin 5 Publications Verification	Infection Structural Classification Punica granatum L. Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Punicaceae Plants Disease Research Fields	SARS-CoV HBV
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL ^pro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 ^[3].

Species:	Virus (5) Human (5) Rhesus Macaque (2) Mouse (2) Rat (1) Cynomolgus (1) Canine (3)
Tag:	His (12) Tag Free (5) Avi (4) Fc (2)
Source:	HEK293 (11) CHO (1) Sf9 insect cells (2) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P78275

SARS-CoV-2 3CLpro/3C-like protease Protein

3C-like protease; 3CL Protease; 3CL-Mpro; 3CL Pro; COVID-19; M Proteinase; Mpro
Virus E. coli

HY-P7429

	SARS-CoV-2 3C-like Proteinase (His) M Proteinase; 3CL Proteinase; 2019-nCoV 3C-like Proteinase	Virus	E. coli
	SARS-CoV-2 3C-like Proteinase (His), His, expressed in E.coli, mediates viral polyprotein maturation and multiple cleavages of host proteins to modulate viral translation and transcription with a His tag at the N-terminus.

HY-P76590

SARS-CoV-2 3CLpro/3C-like protease Protein (His-Avi)

3CL Protease; 3CL Proteinase; 3C-like main protease; 3CL-Mpro; COVID-19; M Proteinase; Main Protease; Mpro
Virus E. coli
HY-P76589

SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His)

3CL Protease; 3CL Proteinase; 3C-like main protease; 3CL-Mpro; COVID-19; M Proteinase; Main Protease; Mpro
Virus Sf9 insect cells
HY-P76591

SARS-CoV-2 3CLpro/3C-like protease Protein (sf9, His-Avi)

3CL Protease; 3CL Proteinase; 3C-like main protease; 3CL-Mpro; COVID-19; M Proteinase; Main Protease; Mpro
Virus Sf9 insect cells

HY-P7355

	Fractalkine/CX3CL1 Protein, Human (CHO) 1 Publications Verification rHuFractalkine/CX3CL1; Fractalkine; CX3CL1; FKN; SCYD1; Neurotactin; NTT	Human	CHO
	Fractalkine/CX3CL1 Protein, Human (CHO) is the member of CX3C chemokine family, associated with many cancers and promotes tumor progression.

HY-P7180

	Fractalkine/CX3CL1 Protein, Human 1 Publications Verification rHuFractalkine/CX3CL1; Neurotactin; SCYD1; NTT	Human	E. coli
	Fractalkine/CX3CL1 Protein, Human is found to be associated with inflammatory diseases such as rheumatoid arthritis (RA), rheumatoid vasculitis (RV).

HY-P75777

	Fractalkine/CX3CL1 Protein, Canine (HEK293) Fractalkine; CX3CL1; FKN; SCYD1; Neurotactin; NTT	Canine	HEK293
	Fractalkine/CX3CL1 Protein, a member of the intercrine beta family, plays a pivotal role in chemokines crucial for intercellular communication and immune responses. Within this family, Fractalkine/CX3CL1 likely modulates inflammatory processes and cellular interactions significantly. Further exploration is essential to unveil its specific functions and implications within the broader chemokine CC family, emphasizing its importance in mediating immune responses and contributing to the intricate network of intercellular signaling. Fractalkine/CX3CL1 Protein, Canine (HEK293) is the recombinant canine-derived Fractalkine/CX3CL1 protein, expressed by HEK293, with tag free. The total length of Fractalkine/CX3CL1 Protein, Canine (HEK293) is 355 a.a., with molecular weight of 64-69 kDa.

HY-P75778

	Fractalkine/CX3CL1 Protein, Canine (HEK293, Fc) Fractalkine; CX3CL1; FKN; SCYD1; Neurotactin; NTT	Canine	HEK293
	Fractalkine/CX3CL1 Protein, a member of the intercrine beta family, plays a pivotal role in chemokines crucial for intercellular communication and immune responses. Within this family, Fractalkine/CX3CL1 likely modulates inflammatory processes and cellular interactions significantly. Further exploration is essential to unveil its specific functions and implications within the broader chemokine CC family, emphasizing its importance in mediating immune responses and contributing to the intricate network of intercellular signaling. Fractalkine/CX3CL1 Protein, Canine (HEK293, Fc) is the recombinant canine-derived Fractalkine/CX3CL1 protein, expressed by HEK293, with C-hFc labeled tag. The total length of Fractalkine/CX3CL1 Protein, Canine (HEK293, Fc) is 379 a.a., with molecular weight of 70-100 kDa.

HY-P75779

	Fractalkine/CX3CL1 Protein, Canine (HEK293, His) Fractalkine; CX3CL1; FKN; SCYD1; Neurotactin; NTT	Canine	HEK293
	Fractalkine/CX3CL1 Protein, a member of the intercrine beta family, plays a pivotal role in chemokines crucial for intercellular communication and immune responses. Within this family, Fractalkine/CX3CL1 likely modulates inflammatory processes and cellular interactions significantly. Further exploration is essential to unveil its specific functions and implications within the broader chemokine CC family, emphasizing its importance in mediating immune responses and contributing to the intricate network of intercellular signaling. Fractalkine/CX3CL1 Protein, Canine (HEK293, His) is the recombinant canine-derived Fractalkine/CX3CL1 protein, expressed by HEK293, with C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Canine (HEK293, His) is 100 a.a., with molecular weight of ~38.9 kDa.

HY-P72686

	Fractalkine/CX3CL1 Protein, Mouse (HEK293, His) 1 Publications Verification Fractalkine; C-X3-C motif chemokine 1; Neurotactin; CX3CL1; FKN; NTT; SCYD1	Mouse	HEK293
	The Fractalkine/CX3CL1 protein is a multifunctional chemokine that binds to CX3CR1 and the integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune responses, inflammation, cell adhesion, and chemotaxis. Fractalkine/CX3CL1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Mouse (HEK293, His) is 313 a.a., with molecular weight of ~55-85 kDa.

HY-P76938

	Fractalkine/CX3CL1 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) Fractalkine; C-X3-C motif chemokine 1; Neurotactin; CX3CL1; FKN; NTT; SCYD1	Rhesus Macaque	HEK293
	Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Fractalkine/CX3CL1 Protein, Cynomolgus/Rhesus Macaque (HEK293, Fc) is 100 a.a., with molecular weight of ~40.8 & 35.2 kDa, respectively.

HY-P76939

	Fractalkine/CX3CL1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) Fractalkine; C-X3-C motif chemokine 1; Neurotactin; CX3CL1; FKN; NTT; SCYD1	Rhesus Macaque	HEK293
	Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Cynomolgus/Rhesus Macaque (HEK293, His) is 100 a.a., with molecular weight of ~10.1 KDa.

HY-P72685

	Fractalkine/CX3CL1 Protein, Human (315a.a, HEK293, His) Fractalkine; C-X3-C motif chemokine 1; Neurotactin; CX3CL1; FKN; NTT; SCYD1	Human	HEK293
	Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Human (315a.a, HEK293, His) is the recombinant human-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Human (315a.a, HEK293, His) is 315 a.a., with molecular weight of 50-90 kDa.

HY-P73070

	Fractalkine/CX3CL1 Protein, Human (339a.a, HEK293, His) Fractalkine; C-X3-C motif chemokine 1; Neurotactin; CX3CL1; FKN; NTT; SCYD1	Human	HEK293
	Fractalkine/CX3CL1 protein, a chemokine, binds CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, chemotaxis, and leukocyte migration. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Human (339a.a, HEK293, His) is the recombinant human-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Human (339a.a, HEK293, His) is 315 a.a., with molecular weight of ~35 kDa.

HY-P700702

	Fractalkine/CX3CL1 Protein, Cynomolgus (HEK293, His) Fractalkine; Neurotactin; Cx3CL1; Cx3c; Fkn; ABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1	Cynomolgus	HEK293
	The Fractalkine/CX3CL1 protein is a member of the intercrine beta family and plays a key role in chemokines that are critical for intercellular communication and immune responses. In this family, Fractalkine/CX3CL1 may significantly regulate inflammatory processes and cellular interactions. Fractalkine/CX3CL1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Cynomolgus (HEK293, His) is 317 a.a., with molecular weight of 50-70 kDa.

HY-P78937

	Fractalkine/CX3CL1 Protein, Human (Biotinylated, HEK293, His) Fractalkine; Neurotactin; Cx3CL1; Cx3c; Fkn; ABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1	Human	HEK293
	Fractalkine/CX3CL1 is a chemokine that acts as a ligand to CX3CR1 and the integrins ITGAV: ITGB3 and ITGA4: ITGB1. CX3CL1 promotes lung cancer cell migration and invasion through the Src/FAK signaling pathway. CX3CL1 plays an important role in immune response, inflammation, cell adhesion and chemotaxis. Fractalkine/CX3CL1 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-Avi, C-10*His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Human (Biotinylated, HEK293, His) is 317 a.a., with molecular weight of 50-90 kDa.

HY-P78113

	Fractalkine/CX3CL1 Protein, Mouse (Biotinylated, HEK293, His-Avi) Fractalkine; Neurotactin; Cx3CL1; Cx3c; Fkn; ABCD-3; C3Xkine; CXC3; CXC3C; NTN; NTT; SCYD1	Mouse	HEK293
	The Fractalkine/CX3CL1 protein is a multifunctional chemokine that binds to CX3CR1 and the integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune responses, inflammation, cell adhesion, and chemotaxis. Fractalkine/CX3CL1 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived Fractalkine/CX3CL1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Fractalkine/CX3CL1 Protein, Mouse (Biotinylated, HEK293, His-Avi) is 312 a.a., with molecular weight of 70-83 kDa.

HY-P79193

	Fractalkine/CX3CL1 Protein, Rat Fractalkine; Cx3CL1; C-X3-C motif chemokine 1; CX3C membrane-anchored chemokine; Neurotactin; Small-inducible cytokine D1; Acc1; Fkn; Scyd1	Rat	E. coli
	Fractalkine/CX3CL1 protein is a versatile chemokine that acts as a ligand for CX3CR1 and integrins ITGAV:ITGB3 and ITGA4:ITGB1. It regulates immune response, inflammation, adhesion, and chemotaxis. It activates integrins via CX3CR1-dependent and -independent pathways, binding to site 1 with CX3CR1 and site 2 without CX3CR1. Soluble Fractalkine/CX3CL1 attracts T-cells and monocytes, not neutrophils. Fractalkine/CX3CL1 Protein, Rat is the recombinant rat-derived Fractalkine/CX3CL1 protein, expressed by E. coli , with tag free. The total length of Fractalkine/CX3CL1 Protein, Rat is 79 a.a., with molecular weight of ~11 kDa.

Cat. No.	Product Name	Chemical Structure

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity ^[3]. Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks